Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

The implantation of bioprosthetic heart valves (BHVs) is increasingly becoming the treatment
of choice in patients requiring heart valve replacement surgery. Unlike mechanical heart …

Objectives The aim of this study was to evaluate early results of valve-in-valve (ViV)
transcatheter aortic valve replacement (TAVR) versus redo surgical aortic valve replacement …

731 F. Beyersdorf and A. Vahanian et al./European Journal of Cardio-Thoracic Surgery
guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ …

Transcatheter aortic valve replacement is now indicated across all risk categories of patients
with symptomatic severe aortic stenosis and has been proposed as first line option for the …

Importance Aortic valve stenosis (AS) is the most common manifestation of acquired valvular
heart disease in developed countries. Several large-scale randomized clinical trials …

Aortic stenosis is the most common valvular disease requiring valve replacement. Valve
replacement therapies have undergone progressive evolution since the 1960s. Over the last …

Background Limited data are available regarding clinical outcomes of valve-in-valve (ViV)
transcatheter aortic valve implantation (TAVI) following the United States Food and Drug …

Objective. Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) has emerged as
a useful alternative intervention to redo-surgical aortic valve replacement (Redo-SVAR) for …

Background: The use of valve-in-valve–transcatheter aortic valve replacement (VIV-TAVR)
in degenerated aortic bioprosthesis has been increasing, but the Food and Drug …